>>The most interesting part of the webcast was the discussion at the end by the practicing hepatologist; however, this material has more relevance to VRTX and MRK than it does to IDIX.<<
Translation? Because they have the protease inhibitors which are going to be the "newest" drug tools to fight HepC? Because they can appreciate the evolution of HepC treatment and have a better understanding of what IDIX's pipeline is really worth ie one of them may want to buy out IDIX???